Skip to main content

Prime Medicine, Inc.

corporate_fare Company Profile

Prime Medicine, Inc.

PRME·NASDAQ·Life Sciences·CIK 0001894562

We are a biotechnology company focused on developing genetic medicines for diseases caused by genetic alterations, cellular dysfunction, or dysregulated gene expression. Our approach uses Prime Editing, a gene editing technology that modifies genomic DNA without creating double-stranded breaks. We believe Prime Editing is a versatile and precise method for rewriting, replacing, or repairing DNA sequences, potentially addressing a broad range of diseases with improved safety and specificity compared to older editing technologies. We are developing wholly owned in vivo programs for liver diseases and Cystic Fibrosis (CF), with support from the Cystic Fibrosis Foundation (CFF). We also have partnered ex vivo programs with Bristol-Myers Squibb (BMS), supported by our modular delivery and Prime Editor platform. Early clinical data from our ex vivo program, PM359 for CGD, showed restored functional protein activity in treated patients, providing clinical validation of Prime Editing and a potentially curative treatment for CGD patients. Our initial development priorities include genetic diseases affecting the liver and lung, and hematologic disorders addressed through ex vivo editing. Our lead program, PM577 for Wilson Disease, aims to correct the H1069Q mutation in the ATP7B gene, supported by preclinical data showing targeted correction and restored copper homeostasis in animal models. We are also developing follow-on Prime Editors for additional ATP7B mutations. Additionally, PM647 is being advanced for alpha-1 antitrypsin deficiency (AATD), another liver-targeted disease.

Prime Medicine, Inc. (NASDAQ:PRME) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for PRME at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for PRME spans 10-Q, 8-K, 424B5, DEF 14A.

Recent high-impact activity:

  • Prime Medicine's Q3 10-Q Flags Going Concern Despite $134.7M Raise and 2027 Runway
  • Prime Medicine Posts Q3 Loss, Pro-Forma Cash of $209.5M and Runway Through 2027
  • Prime Medicine Posts $39M Q3 Operating Loss Days After $125M Raise
  • Prime Medicine Prices $125M Offering at $3.50, a Discount to Monday's Close
  • Prime Medicine Prices $125M Underwritten Stock Offering at $4.30 Reference

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$4.63M
Net Income
-$201.14M
Diluted EPS
-$1.35
Op. Cash Flow
-$162.56M
Free Cash Flow
-$167.09M
Operating Income
-$208.35M
Cash & Equivalents
$63.03M
Debt / Equity
0.00×
Net Margin
-43.42×
Shares Outstanding
180.51M sh
Source: 10-K · filed 2026-03-03 · accession 0001628280-26-013569

Short Interest & Short Volume

4.80 days to cover

FINRA reported short interest of 29,147,049 shares in PRME as of the October 30, 2026 settlement, a 11.3% decrease from the prior period — about 4.8 days to cover at its recent average daily volume. On November 20, 2026, 36.8% of PRME volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)29,147,049 shares as of October 30, 2026
Change vs prior period▼ 11.3%
Days to cover4.80 at avg daily volume of 6,070,767
Daily short volume (FINRA facilities)36.8% of 2,794,695 shares on November 20, 2026
5-day average short volume46.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for PRME, detected from its recent SEC filings · based on capital-structure filings through 2026-11-12.

1 recent capital raise

Final Terms Confirm $125M Offering · Net Proceeds of $117.1 Million

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with P →
$3.56 +0.28% today
52-week range · as of 2026-11-12 $2.67 – $5.91
Market cap
$645.82M
Volume
6.1M (1.1× avg)
3-mo avg 5.5M
Live data · 2026-11-21 21:09 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PRME - Latest Insights

PRME
Nov 12, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.89
Real-time Price: $3.56 info
Change: -$0.3301 (-8%) info
Market Cap: $645.821M info
PRME
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.90
Real-time Price: $3.56 info
Change: -$0.340 (-9%) info
Market Cap: $645.821M info
PRME
Nov 12, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $3.89
Real-time Price: $3.56 info
Change: -$0.330 (-8%) info
Market Cap: $645.821M info
PRME
Nov 10, 2026, 9:41 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $3.76
Real-time Price: $3.56 info
Change: -$0.1995 (-5%) info
Market Cap: $645.821M info
PRME
Nov 10, 2026, 4:43 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.79
Real-time Price: $3.56 info
Change: -$0.230 (-6%) info
Market Cap: $645.821M info
PRME
Nov 10, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $3.56 info
Change: -$0.240 (-6%) info
Market Cap: $645.821M info
PRME
Nov 10, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.81
Real-time Price: $3.56 info
Change: -$0.2501 (-7%) info
Market Cap: $645.821M info
PRME
Oct 28, 2026, 1:53 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.16
Real-time Price: $3.56 info
Change: -$1.60 (-31%) info
Market Cap: $645.821M info
PRME
Sep 24, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.38
Real-time Price: $3.56 info
Change: +$0.1798 (+5%) info
Market Cap: $645.821M info
PRME
Aug 06, 2026, 8:03 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $3.05
Real-time Price: $3.56 info
Change: +$0.510 (+17%) info
Market Cap: $645.821M info
PRME
Aug 06, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.05
Real-time Price: $3.56 info
Change: +$0.510 (+17%) info
Market Cap: $645.821M info
PRME
Jul 23, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.08
Real-time Price: $3.56 info
Change: +$0.480 (+16%) info
Market Cap: $645.821M info
PRME
Jul 08, 2026, 8:03 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $4.00
Real-time Price: $3.56 info
Change: -$0.440 (-11%) info
Market Cap: $645.821M info
PRME
Jul 08, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.53
Real-time Price: $3.56 info
Change: -$0.970 (-21%) info
Market Cap: $645.821M info
PRME
Jun 22, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.24
Real-time Price: $3.56 info
Change: +$0.320 (+10%) info
Market Cap: $645.821M info
PRME
Jun 18, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.09
Real-time Price: $3.56 info
Change: +$0.470 (+15%) info
Market Cap: $645.821M info
PRME
May 07, 2026, 8:15 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.38
Real-time Price: $3.56 info
Change: +$0.180 (+5%) info
Market Cap: $645.821M info
PRME
May 07, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.38
Real-time Price: $3.56 info
Change: +$0.180 (+5%) info
Market Cap: $645.821M info
PRME
May 07, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.38
Real-time Price: $3.56 info
Change: +$0.180 (+5%) info
Market Cap: $645.821M info
PRME
Apr 23, 2026, 8:35 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $3.96
Real-time Price: $3.56 info
Change: -$0.395 (-10%) info
Market Cap: $645.821M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets